Janney Montgomery Scott LLC Sells 2,577 Shares of AstraZeneca plc (AZN)

Janney Montgomery Scott LLC cut its holdings in AstraZeneca plc (NYSE:AZN) by 2.1% during the fourth quarter, Holdings Channel reports. The firm owned 118,785 shares of the company’s stock after selling 2,577 shares during the quarter. Janney Montgomery Scott LLC’s holdings in AstraZeneca were worth $4,511,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Legacy Financial Advisors Inc. increased its holdings in AstraZeneca by 38.6% during the fourth quarter. Legacy Financial Advisors Inc. now owns 2,031 shares of the company’s stock worth $77,000 after buying an additional 566 shares during the last quarter. CWM LLC increased its holdings in AstraZeneca by 122.2% during the fourth quarter. CWM LLC now owns 2,827 shares of the company’s stock worth $107,000 after buying an additional 1,555 shares during the last quarter. Factorial Partners LLC acquired a new position in AstraZeneca during the third quarter worth $119,000. We Are One Seven LLC acquired a new position in AstraZeneca during the fourth quarter worth $121,000. Finally, Sit Investment Associates Inc. acquired a new position in AstraZeneca during the fourth quarter worth $171,000. Institutional investors and hedge funds own 17.27% of the company’s stock.

AZN has been the topic of a number of recent analyst reports. Deutsche Bank restated a “buy” rating on shares of AstraZeneca in a report on Monday, November 12th. Credit Suisse Group restated a “buy” rating on shares of AstraZeneca in a report on Sunday, December 9th. ValuEngine upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Thursday, December 13th. SunTrust Banks initiated coverage on shares of AstraZeneca in a report on Thursday, December 13th. They set a “buy” rating and a $48.00 target price on the stock. Finally, Bank of America restated a “buy” rating on shares of AstraZeneca in a report on Friday, December 14th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $45.50.

AZN stock opened at $37.01 on Monday. The company has a debt-to-equity ratio of 1.36, a current ratio of 0.86 and a quick ratio of 0.66. AstraZeneca plc has a one year low of $32.69 and a one year high of $41.78. The firm has a market cap of $93.74 billion, a price-to-earnings ratio of 8.65, a P/E/G ratio of 1.96 and a beta of 0.51.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, November 8th. The company reported $0.71 EPS for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.38. The firm had revenue of $5.34 billion during the quarter, compared to analysts’ expectations of $5.26 billion. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. The company’s revenue for the quarter was down 14.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.12 earnings per share. As a group, sell-side analysts anticipate that AstraZeneca plc will post 1.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Janney Montgomery Scott LLC Sells 2,577 Shares of AstraZeneca plc (AZN)” was first published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.wkrb13.com/2019/02/11/janney-montgomery-scott-llc-sells-2577-shares-of-astrazeneca-plc-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Trading Penny Stocks

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply